window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Infectious Diseases

  • Manufacturing & Supply Chain

    University Hospital Cologne selects Celonic for anti-Pseudomonas antibody manufacturing

    University Hospital Cologne has selected Celonic as its CDMO partner [...]

    August 13, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Seegene data finds STI pathogens in 82% of HPV-positive test results

    Seegene analysis of about 60,000 test results found STI pathogens [...]

    July 28, 2026
  • Digital & Data,Research & Development,Therapeutic Areas

    Fleming Initiative selects AWS to support global antimicrobial resistance platform

    The Fleming Initiative has selected Amazon Web Services (AWS) to [...]

    July 3, 2026
  • Drug Discovery & Development,Therapeutic Areas

    Circio and University of Texas Medical Branch partner on infectious disease research using circular RNA

    Circio has entered a research collaboration with the University of [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Medical devices,Therapeutic Areas

    En Carta Diagnostics receives FDA breakthrough device designation for Lyme disease test

    En Carta Diagnostics has received FDA Breakthrough Device Designation for [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gilead reports positive Phase 3 results for single-tablet HIV regimen

    Gilead Sciences has announced positive topline results from the Phase [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Cidara Therapeutics receives FDA Breakthrough Therapy designation for CD388 in seasonal influenza prevention

    Cidara Therapeutics has received Breakthrough Therapy designation from the US [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Opinion & Events,Pharmaceuticals and therapeutics

    Kling Bio and Sanofi join forces to speed discovery of neutralizing antibodies

    Kling Bio has announced a collaboration and license option agreement [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Kling Bio and Sanofi collaborate to accelerate discovery of next-generation antiviral antibodies

    Biotech company Kling Bio has announced a new collaboration with [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development

    Faster equine respiratory disease testing with bioMérieux’s new Vetfire PCR panel

    With Vetfire, bioMérieux enters the veterinary PCR market with an [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Tufts analysis finds AI clinical monitoring could cut trial costs and development time
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Research & Development
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top